144 related articles for article (PubMed ID: 33111621)
1. A molecular dynamics and docking study to screen anti-cancer compounds targeting mutated p53.
Shah HD; Saranath D; Murthy V
J Biomol Struct Dyn; 2022 Apr; 40(6):2407-2416. PubMed ID: 33111621
[TBL] [Abstract][Full Text] [Related]
2. Discovery of anti-colon cancer agents targeting wild-type and mutant p53 using computer-aided drug design.
Hadni H; Elhallaoui M
J Biomol Struct Dyn; 2023 Nov; 41(19):10171-10189. PubMed ID: 36533393
[TBL] [Abstract][Full Text] [Related]
3. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics.
Garg S; Singh J; Verma SR
J Mol Model; 2023 Jan; 29(2):55. PubMed ID: 36700982
[TBL] [Abstract][Full Text] [Related]
4. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.
Zhang Q; Bykov VJN; Wiman KG; Zawacka-Pankau J
Cell Death Dis; 2018 May; 9(5):439. PubMed ID: 29670092
[TBL] [Abstract][Full Text] [Related]
5.
Meher RK; Mir SA; Anisetti SS
J Biomol Struct Dyn; 2024 May; 42(8):4169-4184. PubMed ID: 37272907
[TBL] [Abstract][Full Text] [Related]
6. Wild type p53 function in p53
Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373
[TBL] [Abstract][Full Text] [Related]
7. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53.
Wassman CD; Baronio R; Demir Ö; Wallentine BD; Chen CK; Hall LV; Salehi F; Lin DW; Chung BP; Hatfield GW; Richard Chamberlin A; Luecke H; Lathrop RH; Kaiser P; Amaro RE
Nat Commun; 2013; 4():1407. PubMed ID: 23360998
[TBL] [Abstract][Full Text] [Related]
8. An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.
Bromley D; Bauer MR; Fersht AR; Daggett V
Protein Eng Des Sel; 2016 Sep; 29(9):377-90. PubMed ID: 27503952
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy.
Ahire V; Das D; Mishra KP; Kulkarni GR; Ackland L
J Environ Pathol Toxicol Oncol; 2016; 35(4):355-364. PubMed ID: 27992315
[TBL] [Abstract][Full Text] [Related]
10. R248Q mutation--Beyond p53-DNA binding.
Ng JW; Lama D; Lukman S; Lane DP; Verma CS; Sim AY
Proteins; 2015 Dec; 83(12):2240-50. PubMed ID: 26442703
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 as a target for cancer treatment.
Duffy MJ; Synnott NC; Crown J
Eur J Cancer; 2017 Sep; 83():258-265. PubMed ID: 28756138
[TBL] [Abstract][Full Text] [Related]
12. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening.
Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M
J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488
[TBL] [Abstract][Full Text] [Related]
13. Dynamic perspectives into the mechanisms of mutation-induced p53-DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy.
Olotu FA; Soliman MES
J Cell Biochem; 2019 Jan; 120(1):951-966. PubMed ID: 30160791
[TBL] [Abstract][Full Text] [Related]
14. Virtual Screening Based on Ensemble Docking Targeting Wild-Type p53 for Anticancer Drug Discovery.
Li X; Zhang XX; Lin YX; Xu XM; Li L; Yang JB
Chem Biodivers; 2019 Jul; 16(7):e1900170. PubMed ID: 31134745
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 reactivation by small molecules makes its way to the clinic.
Bykov VJ; Wiman KG
FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
[TBL] [Abstract][Full Text] [Related]
16. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
[TBL] [Abstract][Full Text] [Related]
17. Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties.
Omar SI; Tuszynski J
Chem Biol Drug Des; 2015 Aug; 86(2):163-72. PubMed ID: 25407396
[TBL] [Abstract][Full Text] [Related]
18. In-silico identification of small molecules targeting H-Ras and in-vitro cytotoxicity with caspase-mediated apoptosis in carcinoma cells.
Damani Shah H; Saranath D; Das S; Kharkar P; Karande A
J Cell Biochem; 2019 Apr; 120(4):5519-5530. PubMed ID: 30367521
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening using covalent docking to find activators for G245S mutant p53.
Omar SI; Lepre MG; Morbiducci U; Deriu MA; Tuszynski JA
PLoS One; 2018; 13(9):e0200769. PubMed ID: 30192754
[TBL] [Abstract][Full Text] [Related]
20. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
